MAPT and Alzheimer disease: Studies in AD have revealed that increased phosphorylated tau levels, including both p-tau181 and p-tau231, correlate with neocortical neurofibrillary burden in AD [26, 27], though a similar relationship in CTE between elevated CSF p-tau231 levels and increased p-tau accumulation in the neocortex has not been well-investigated.